reports
AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Tr...
AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb Ischemia TOKYO, April 05, 2019 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for treating serious diseases, announced today that they have obtained conditional approval (“Approval with Conditions and Time Limit”) from the Japanese Ministry of Health, Labour and Welfare (MHLW) for HGF plasmid to treat patients with critical limb ischemia (CLI). HGF plasmid is the first gene therapy product to be approved in Japan, for the improvement ...
Vasomune Therapeutics and AnGes, Inc. enter into a Multi-Million Dolla...
Vasomune Therapeutics and AnGes, Inc. enter into a Multi-Million Dollar Global Co-Development Agreement to Advance an Innovative Platform Targeting Vascular Leakage TOKYO and TORONTO, July 31, 2018 (GLOBE NEWSWIRE) -- Vasomune Therapeutics (“Vasomune”), a Toronto-based spin-out from Sunnybrook Research Institute and MaRS Innovation, and AnGes, Inc. (Tokyo, TYO:4563), a Japan-based biotechnology company focused on developing biotherapeutics, announce the signing of an innovative global Co-Development Agreement for the development and commercialization of therapeutics treating diseases asso...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.